#19,150
As we've discussed often, it takes a certain amount of luck for novel flu infections to be detected, properly treated, and then reported to the CDC. It seems likely that some number of mild illnesses go unrecognized (see MMWR: Serologic Evidence of Recent Infection with HPAI A(H5) Virus Among Dairy Workers) , and even severe cases can be misdiagnosed.
We've seen instances where patients were only diagnosed retrospectively; sometimes well after they had been treated and released from the hospital (see 2024 Missouri case).
Standard rapid influenza tests don't distinguish between seasonal and novel flu strains, and sometimes, repeated swabs of the upper airway can fail to `capture' a deep lung infection for RT-PCR testing.
Such is the case of the fatal H5N5 case, reported last November, from Washington state, according to a detailed MMWR report published yesterday by the CDC As the graphic at the top of this blog shows, the patient repeatedly tested negative for influenza/COVID during the first 6 days of his hospitalization.
Not surprisingly, a large number (n=139) of hospital personnel and other close contacts were exposed to this patient before he was moved to an isolation unit.
While no secondary transmissions were reported, it appears only those contacts reporting flu-like symptoms were tested by RT-PCR (NP swabs), and I could find no mention of follow-up serological testing.
Given this is the first known human infection with novel H5N5, I would have thought a wider net would have been cast. But that's just me, I guess. Perhaps there's another study in the pipeline on this.
In any event, the takeaway here appears to be that when dealing with a respiratory infection with someone with contact with poultry or wild birds, a high index of suspicion is warranted, and taking samples from both the upper and lower respiratory tract is recommended.
Fatal Human Case of Highly Pathogenic Avian Influenza A(H5N5) in a Backyard Flock Owner — Washington, November 2025
Weekly / May 7, 2026 / 75(17);221–225
Lynae Kibiger, MPH1; Hanna N. Oltean, PhD1,2; Lisa Leitz3; Emma Krause3; Debra Barrett3; Anna Halloran, MHPA1; Kyle Yomogida, PhD1; Beth Lipton, DVM1; Keely Paris, MPH1; Jared Keirn, MS1; Minden Buswell, DVM1; Allison Black, PhD1; Pauline Trinh, PhD1; Theresa Murray, MT1; Roberto Bonaccorso1; Leticia Banuelos1; Ethan Dieringer1; Jennifer Lenahan, MPH4; Emily Spence Davizon, MPH4; Ellyn P. Marder, DrPH2,4; Jocelyn Mullins, DVM, PhD4; Meagan Kay, DVM2,4; Eric J. Chow, MD2,4,5,6; Sandra J. Valenciano, MD4; John Lynch, MD5,7; Vanessa Makarewicz, MN7; Chloe Bryson-Cahn, MD5,7; Jennifer Hernandez7; Kyla Haggith7; Valicia Linn7; Alex L. Greninger, MD, PhD8; Stephanie Goya, PhD8; Sierra Gulla9; Jennifer Young, MPH9; Sierra Kerns-Funk, MPH10; Brianna da Silva Bhatia, MD10; Hollianne Bruce, MPH11; Krista Kniss, MPH12; Katie Reinhart, PhD12; Rachel Ohlstein13; Shannon Johnson13; Christina Schofield, MD14; Patrick Smith, DO14; Amber Itle, VMD15; Maura Gibson, DVM16; Brandi Torrevillas17; Azeza Falghoush, PhD17; Thomas B. Waltzek, DVM, PhD17; Kevin Snekvik, DVM, PhD17; Mia Torchetti, DVM, PhD16; Timothy M. Uyeki, MD12; Scott Lindquist, MD1 (VIEW AUTHOR AFFILIATIONS)View suggested citation
Summary
What is already known about this topic?
Since 2022, highly pathogenic avian influenza (HPAI) A(H5) viruses have circulated among wild birds in the United States. Seventy human cases of influenza A(H5), most with mild illness, have been reported in the United States since 2024; 14 human influenza A(H5N1) cases were previously identified in Washington.
What is added by this report?
In November 2025, Washington reported the first human case of HPAI A(H5N5) infection worldwide. A positive laboratory result was obtained from a lower respiratory sample after multiple negative upper respiratory sample results; the patient experienced respiratory failure and died 28 days after symptom onset. The public health investigation identified approximately 135 exposed persons.
What are the implications for public health practice?
Symptom management and testing of exposed persons are critical to monitoring for human-to-human transmission of novel influenza infection. Environmental and animal investigations, including genomic analysis, can identify epidemiologic risk factors.ls
Article PDF
Full Issue PDF
Abstract
Clade 2.3.4.4b influenza A(H5N1) viruses have circulated across migratory bird flyways in the United States since 2022, including in Washington, where backyard flock detections have been reported annually. In November 2025, a Washington resident died from acute respiratory failure after receiving a positive influenza A(H5) test result at a hospital laboratory.Washington Public Health Laboratories confirmed influenza A(H5), and genomic sequencing identified influenza A(H5N5) virus (A6 genotype). Polymerase chain reaction testing detected highly pathogenic avian influenza A(H5) virus clade 2.3.4.4b from an apparently healthy backyard flock of ducks and sediment from a watering basin on the patient’s property. Six of eight gene segments from the environmental sample and one duck sample (partial neuraminidase segment) were highly genetically similar to the patient’s virus sequence.Although existing wild bird surveillance had not detected influenza A(H5N5) virus (A6) in the U.S. Pacific Flyway, introduction via wild birds into the environment of the backyard flock was likely the source of the patient’s exposure.The public health investigation identified approximately 135 exposed persons; symptom monitoring and influenza testing detected no additional cases. The overall risk for avian influenza A remains low among the general U.S. population; however, novel avian influenza A virus infection should be considered in persons with symptoms of influenza and potential exposures.
(SNIP)
The diagnosis of influenza A(H5N5) virus infection in the patient described in this report was complicated by early and repeated negative influenza test results from upper respiratory swab specimens. Negative influenza results from initial upper respiratory specimens have been described in three similar patients with lower respiratory tract disease hospitalized with avian influenza A(H5N1) infection (4). Thus, avian influenza virus infection should not be ruled out in hospitalized patients based on negative influenza laboratory test results from upper respiratory tract specimens if the patients have lower respiratory tract disease, relevant exposures, and no confirmed etiology for their disease. If avian influenza virus infection is suspected in a patient with severe respiratory disease, both upper and lower respiratory tract specimens should be collected for influenza testing by RT-PCR at a public health laboratory (6).(Continue . . . )
Early negative influenza results delayed initiation of isolation precautions, reporting to public health authorities, and symptom monitoring. Although isolation precautions were not established consistently until the ninth day of inpatient care, no cases among HCP were identified. Likewise, no cases were detected among family members, despite lengthy exposure to both the symptomatic patient and the property. One household member reported direct contact with the ill and dead ducks but remained asymptomatic. Establishing a tiered risk assessment for HCP exposures based on setting and PPE use allowed staff members to continue working while having their symptoms monitored and limited new HCP exposures. The investigation was complicated by its occurrence during viral respiratory season and symptom development among several persons whose symptoms were being monitored. Human-to-human transmission of avian influenza A viruses has only rarely been reported globally and has not been reported in the United States (3,7).
Timely HPAI risk evaluation is important for persons with influenza symptoms requiring hospitalization to support infection prevention and control, early notification of public health authorities, and robust epidemiologic investigation, including genomic sequencing to identify possible transmission pathways. Ill or dead animals should be reported to animal health authorities for surveillance and potential testing and to reduce human exposure. Public health guidance for evaluating suspected cases of avian influenza should include immediate isolation precautions, prompt initiation of antiviral treatment, repeated influenza testing, and specimen collection from multiple sites (2,6,8). Considering the successive influenza A–negative laboratory results in the Washington patient, sampling from both upper and lower respiratory tracts in hospitalized patients should be considered to increase the likelihood of laboratory detection.
While the exact exposure to H5N5 remains uncertain, it is likely that unprotected (mask, eye protection, gloves) with wild backyard birds was the source of this fatal infection.
This is remarkably similar to the fatal case reported earlier in 2025 in Louisiana.
There are reportedly more than 11 million backyard poultry flocks in the United States, and tens of millions more in Europe and Asia. That's a lot of opportunities for spillovers.
Last October, in UF/IFAS Extension: What Backyard Flock Owners Need to Know about Bird Flu (Influenza H5N1), we looked at two H5N1 related publications; one for backyard poultry owners, and another for consumers of poultry products and milk.
While there's plenty of useful guidance out there, getting people to follow it is another thing entirely.
